NCT03003728 - 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) | Biotech Hunter

Timeline

Start Date

November 1, 2019

Primary Completion Date

July 8, 2020

Study Completion Date

July 8, 2020

Conditions

Multiple Myeloma

Interventions

DRUG

Elotuzumab

Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26

DRUG

Melphalan

Melphalan 200 mg/m2 Ivia intravenous infusion on day -3

PROCEDURE

Autologous Stem Cell Transplant (ASCT)

ASCT on day -2

BIOLOGICAL

Expanded Natural Killer (ENK) Cells

ENK cell infusion on day 0

DRUG

ALT-803

ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22

Trial Locations (1)

University of Arkansas for Medical Sciences, Little Rock